Clinics and Practice, Free Full-Text

Over the years, immune checkpoint inhibitors (CPIs) have become a powerful treatment strategy in the field of cancer immunotherapy. In the last decade, the number of FDA-approved CPIs has been increasing prominently, opening new horizons for the treatment of a wide range of tumor types. Pointedly, three immune checkpoint molecules have been under extensive research, which include cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) and its ligand-1 (PD-L1). Despite remarkable success, not all patients respond positively to therapy, which highlights the complexity of the tumor microenvironment (TME) and immune system. This has led to the identification of molecular biomarkers to predict response and toxicity. In addition, there has been an emerging focus on developing new delivery and targeting approaches for better drug efficacy and potency. In this review, we highlight the mechanism of action of major CPIs, their clinical impact, variation in effectiveness, response prediction, updated clinical indications, current challenges and limitations, promising novel approaches, and future directions.

Clinics and Practice An Open Access Journal from MDPI

Clinics and Practice An Open Access Journal from MDPI

Assessment of patient follow-up from student-run free eye clinic to county ophthalmology clinic

Psychiatric Research and Clinical Practice - Wiley Online Library

A survey on clinical natural language processing in the United Kingdom from 2007 to 2022

Addressing Barriers to APRN Practice: Policy and Regulatory Implications During COVID-19 - Journal of Nursing Regulation

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines